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A report on the Keystone Symposium ‘Proteomics:
Technologies and Applications’, Keystone, USA, 25-30
March 2003.
The Keystone Symposium ‘Proteomics: Technologies and
Applications’ might have passed as a joint convention of
puzzle fanatics and auto mechanics. Analytical chemists,
computational biologists, and geneticists rubbed shoulders
as they presented the ‘bleeding edge’ of proteomics, a field at
whose heart is a central question: how do we take the parts
lists of genes from genome-sequencing projects and learn
how the thousands of encoded proteins work and interact in
the cell? Speakers at the symposium presented ever more
sophisticated approaches to tease out subtle relationships
among proteins, always with an eye towards understanding
how to cope with the copious data generated by high-
throughput approaches. 
Tony Pawson (Mount Sinai Hospital, Toronto, Canada) gave
the opening address, posing the question, which would recur
during the conference, of whether the prevalence of interact-
ing protein domains allows cells to create new signaling path-
ways more easily. To illustrate this idea, Pawson described
the creation of a functional signaling pathway that does not
exist naturally. In normal mice, receptor tyrosine kinases are
involved in transmitting signals for cell growth, whereas
death receptors provide the signal for apoptosis. Pawson
described ‘re-routing’ receptor tyrosine kinases, by changing
their intracellular interaction domains, leading to a swap in
the receptors’ signaling targets and thereby inducing apoptosis
from a receptor that normally signals growth. This notion of
reprogramming signaling pathways by changing interaction
domains was later reinforced by Alissa Resch (University of
California, Los Angeles, USA), who presented tantalizing
evidence that one function of alternate gene splicing might be
to activate different subnetworks of interacting proteins by
selectively adding or removing protein interaction domains.
Pawson also described in some detail an approach for creating
transgenic mice that appears extremely promising for scaling
up functional studies of mouse genes. Using in vivo expression
of plasmid-based short hairpin RNA, Pawson demonstrated
that he could down-regulate the GTPase-activating protein
RasGAP p120 in embryonic stem cells. Subjecting the stem
cells to tetraploid aggregation and subsequent embryogenesis
leads to the formation of aberrant mouse embryos; this
process is much quicker than the traditional route to generat-
ing knockout mice using homologous recombination, taking
only about 3 weeks rather than months. The talk set the stage
well for the conference to come: although it focused strongly on
the underlying biology, it shifted - inevitably - to the technology
required to study these ideas on a genome-wide scale.
Brute-force proteomics
As a field, proteomics is unashamedly high-throughput, and
a clear trend at the symposium was the high-throughput
direct assault on cellular systems, an approach exemplified by
the talk given by Ruedi Aebersold (Institute for Systems
Biology, Seattle, USA). He described the increasingly popular
conception of proteomics not simply as the construction of a
second parts list - the list of expressed proteins - but as an
assay system. According to this idea, quantitative measure-
ment of the proteome serves as a ‘phenotype’ for the cell and
requires accurate, rapid, and replicable measurement of the
concentration of each expressed protein. Ironically, although
experimental technology such as mass spectrometry is cur-
rently capable of meeting these demands, the ability to inter-
pret the data fully lags behind. In Aebersold’s estimate, the
technology has matured to the point where the experiment
itself requires perhaps only around 15% of the researcher’s
time; approximately 10% of the time is spent analyzing the
data to identify and quantify proteins while, in the major
bottleneck at this stage, around 70% of the time is spent
verifying that the protein assignments are correct, often by
manual checking of the raw data. This need for manual
analysis was echoed by Bruno Domon (Celera GenomicsGroup, Rockville, USA), who described in detail the extensive
manual data checking performed to verify mass spectrometry
peptide assignments, which is aided in ambiguous cases by
the addition of synthetic peptides to samples in order to
confirm the identities of important proteins.
Pavel Pevzner (University of California, San Diego, USA)
described computational efforts to sidestep this demanding
manual examination of raw data. He presented the develop-
ment of algorithms that can better identify peptides from
experimental peptide fragmentation spectra, even in the
presence of up to two post-translational modifications.
Pevzner pointed out that one difficulty in this area of
research is the dearth of publicly available mass spectrome-
try proteomics data, which complicates the development and
testing of algorithms. A public repository of proteomics data
could therefore potentially spur a great deal of research in
this area, much as has happened for DNA microarrays and
genome sequence data. A number of other talks addressed
the need for quantitative benchmarking of proteomics
results, including the talk by Josh Elias (Harvard Medical
School, Boston, USA), who described how to interpret mass
spectra by learning quantitative trends in the types of
peptide fragmentation ions actually observed. 
Fitting the pieces together
Along with large-scale efforts to characterize protein expres-
sion, efforts to define protein-interaction networks were also
well represented. Stanley Fields (University of Washington,
Seattle, USA) described an effort to develop a ‘yeast two-
hybrid-like’ system specifically for membrane proteins,
which have tended to be omitted from high-throughput
assays. Fields’ approach is to use a split-ubiquitin assay, in
which the amino- and carboxy-terminal halves of ubiquitin
are each fused to a set of approximately 700 yeast integral
membrane proteins; the carboxy-terminal fusions also
encode a LexA/Vp16 transcription factor. Interaction
between a pair of membrane proteins reconstitutes ubiqui-
tin, triggering proteolysis by ubiquitin-specific proteases,
which releases the transcription factor and consequently
stimulates transcription of a reporter gene. Early results
show that the method successfully finds interacting mem-
brane proteins, albeit with a reasonably high false-positive
rate. Steven Michnick (Université de Montréal, Canada)
described measuring protein interactions by using protein-
fragment complementation assays together with a fluores-
cent assay. By reconstituting green fluorescent protein or
dihydrofolate reductase, the latter detected via binding of a
fluorescent substrate, the cellular location of the protein
interactions could be observed, suggesting that, in addition
to cataloging protein interactions, it may also soon be possi-
ble to follow their spatial and temporal dynamics in the cell. 
Scaling up two-hybrid screens to measure protein interactions
across a complete proteome presents numerous problems,
including that of cloning and expressing the thousands of
necessary proteins. Marc Vidal (Dana Farber Cancer Insti-
tute, Boston, USA) described the current state of all-versus-
all protein-interaction screening in the nematode
Caenorhabditis elegans. More than 12,000 of the approxi-
mately 20,000 predicted open reading frames in C. elegans
have now been successfully cloned from a cDNA library into
recombinational cloning vectors. Vidal reported that by
transferring clones into yeast two-hybrid expression vectors,
his group has identified roughly 1,500 interactions between
more than 1,200 proteins. 
A highlight of the protein-interaction talks was the presenta-
tion by Michael Snyder (Yale University, New Haven, USA),
who detailed the comprehensive biochemical assaying of
yeast proteins. Having cloned 5,800 yeast proteins and
expressed them as fusion proteins, then affinity purified the
products using the fused tag, the proteins have been printed
onto microarray slides. Although a large fraction of the pro-
teins are no doubt improperly folded, the resulting array had
a sufficient fraction of properly expressed and folded pro-
teins that they could be assayed for biochemical or binding
activities. For example, screening with calmodulin revealed
33 new binding targets, while screening with 14-3-3 proteins
revealed 140 new binding partners, several of which were
independently verified by co-immunoprecipitation. 
The power of such protein microarrays for systematic assays
was reiterated by Dolores Cahill (Max Planck Institute for
Molecular Genetics, Berlin, Germany), who described creat-
ing microarrays with around 37,000 human proteins
expressed from cDNA expression clones in Escherichia coli.
Cahill screened the arrays with antibody-containing sera in
order to characterize the spectrum of binding specificities
within each serum sample. She speculated that in this way it
would be possible to rapidly screen sera to detect autoimmune
disorders or otherwise characterize the state of the immune
system. Gavin MacBeath (Harvard University, Cambridge,
USA) described the use of protein arrays for high-throughput
screening of small-molecule inhibitors that disrupt protein
interactions. He described how to scale up the search for
active inhibitors and simultaneously characterize inhibitor
specificity by constructing the arrays directly in the wells of
microtiter dishes.
But what do the proteins do?
Teasing out the precise functions of proteins on such a large
scale would seem to be an even more daunting task than
following their expression or interactions. But a number of
clever approaches were described that gave some indications
as to how this problem will ultimately be approached.
Andrew Fraser (Wellcome Trust Sanger Institute, Cambridge,
UK) described the use of RNA interference (RNAi) to
attempt to inactivate around 17,000 C. elegans genes.
Through a curious trick of fate, when E. coli expressing
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suppressing expression of the corresponding genes. Fraser
and colleagues cloned and expressed each worm gene in
E. coli, fed the bacteria to worms, and assayed the worms for
knockout phenotypes, detecting phenotypes for around
1,700 genes. Fraser described systematic analyses using
these data of relationships between gene function and posi-
tion, including the strong selection against essential genes
appearing on the X chromosome and the tendency for neigh-
boring genes to share RNAi phenotypes. Interestingly,
Fraser noted that genes that are in the same SL2 ribonucleo-
protein-dependent trans-spliced ‘operons’, the worm equiv-
alent of bacterial operons as recently characterized by Stuart
Kim and colleagues, often do not appear to share RNAi pheno-
types, raising the question of whether worm genes in the
same operon will generally be functionally related, as is the
case for bacterial genes encoded in the same operon.
A simple, but powerful, functional assay was described by
Benjamin Cravatt (Scripps Research Institute, La Jolla, USA)
for profiling the set of enzymes with a given general type of
catalytic activity. In this activity-based profiling approach,
enzyme substrates were synthesized with a reactive group and
a fluorophore, such that the substrate cross-links to the
general class of enzyme acting upon this type of substrate. By
adding these hybrid substrate reagents to cells grown under
different conditions, the subpopulation of active enzymes with
the appropriate specificity could be monitored or purified.
Using this approach, Cravatt described the design of a poten-
tial analgesic to inhibit fatty acid amide hydrolase (FAAH), the
serine hydrolase that regulates signaling by the endocannabi-
noid CB1. The active component of marijuana, tetrahydro-
cannabinol (THC), is a CB1 agonist, so Cravatt speculated that
blocking FAAH might promote analgesia while avoiding the
other side effects of THC. Current FAAH inhibitors cross react
with many FAAH-like serine hydrolases, but by using activity-
based profiling, Cravatt could screen FAAH inhibitors for
their in vivo selectivity, and in this manner was able to iden-
tify a specific FAAH inhibitor. Interestingly, during this
process, a selective inhibitor was developed for a second
FAAH-like protease that has yet to be characterized, meaning
that a specific inhibitor was developed for an enzyme before
ever knowing the enzyme’s natural substrate.
Three-dimensional puzzles
Another highlight of the symposium was a presentation by
Joachim Frank (Wadsworth Center, State University of New
York, Albany, USA), who described the current state of
knowledge of the E. coli ribosome structure obtained using
single-particle reconstruction by cryoelectron microscopy.
More than 110,000 individual ribosome images have now
been integrated into Frank’s model structure, which has
been fitted with the recently solved X-ray crystal structures
of ribosomal proteins to create a hybrid atomic-
resolution/cryo-EM ribosome structure. Frank described the
complex movements taking place in the ribosome during the
processes of peptide-bond formation and ribosome stalling,
which were revealed in beautiful modeling movies. Perhaps
most striking was the extent to which the ribosomal proteins
appeared to shift positions, suggesting they might play active
roles in the mechanical movement of the ribosome.
A similarly detailed picture of the yeast nuclear pore
complex is not yet available, but Andrej Šali (University of
California, San Francisco, USA) and Brian Chait (Rockefeller
University, New York, USA) described progress in this area.
By combining Chait’s experimental data on the distribution
of proteins of the nuclear pore complex with other con-
straints such as estimated protein sizes and known protein
interactions, Šali described the computational construction
of a nuclear pore complex model that satisfied all of the
available constraints, including the known symmetry of the
complex. The model is a work in progress, but the approach
taken allows for the inclusion of many diverse forms of
experimental data, suggesting that it can only become more
accurate as additional data are added.
Finally, starting from a protein’s structure, David Baker
(University of Washington, Seattle, USA) described how one
might begin to design protein-protein interactions. Starting
with an algorithm that finds amino-acid sequences that pack
well into a fixed protein structure, Baker described how the
approach  could be generalized to create a new interface
between two DNA-binding domains of known structure.
Experimental construction of the designed proteins con-
firmed that they do in fact interact and bind to a novel
DNA sequence.
In summary, progress in proteomics has been rapid, and the
sheer scale of the projects presented makes for news in itself.
The field is still quite far from solving the proteomics jigsaw
puzzle, however, and researchers are grappling with under-
standing the emergent complexity. In the closing words of
conference organizer Aebersold, “We don’t really know what
it all means, but I’m sure it’s interesting”. 
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